Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a survival rate
less than 5%. Multiple chemotherapeutic drugs have been tested to improve patient …

Background Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer that is
characterized by its poor prognosis, rapid progression and development of drug resistance …

Objectives A limited repertoire of good pancreatic ductal adenocarcinoma (PDAC) models is
one of the main barriers in developing effective new PDAC treatments. We aimed to …

Pancreatic ductal adenocarcinoma (PDA) is an extremely lethal malignancy arising from the
pancreas. The treatment of PDA is complicated by ineffective treatments and a lack of …

Adjuvant chemotherapy benefits patients with resected pancreatic ductal adenocarcinoma
(PDAC), but the compromised physical state of post-operative patients can hinder …

The myelocytomatosis oncogene (MYC) is an important driver in a subtype of pancreatic
ductal adenocarcinoma (PDAC). However, MYC remains a challenging therapeutic target; …

Pancreatic ductal adenocarcinoma (PDAC) harbors the worst prognosis of any common
solid tumor, and multiple failed clinical trials indicate therapeutic recalcitrance. Here, we use …

A major impediment to the effective treatment of patients with pancreatic ductal
adenocarcinoma (PDAC) is the molecular heterogeneity of this disease, which is reflected in …

Over the last decade, many of the major solid organ cancers have seen improvements in
survival due to development of novel therapeutics and corresponding biomarkers that …

Background Pancreatic ductal adenocarcinoma (PDAC) has been widely studied at
multiomics level. However, little is known about its specific ubiquitination, a major post …